Antifungal Susceptibility Testing with Etest for Candida Species Isolated from Patients with Oral Candidiasis
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: The necessity of performing antifungal susceptibility tests is recently increasing because of frequent cases of oral candidiasis caused by antifungal-resistant Candida species. The Etest (BioMerieux, Marcy l'Etoile, France) is a rapid and easy-to-perform in vitro antifungal susceptibility test. Objective: The purpose of this study was to determine the minimal inhibitory concentrations (MICs) of antifungal agents by using the Etest for Candida species isolated from patients with oral candidiasis. Methods: Forty-seven clinical isolates of Candida species (39 isolates of Candida albicans, 5 isolates of C. glabrata, and 3 isolates of C. tropicalis) were tested along with a reference strain (C. albicans ATCC 90028). The MIC end points of the Etest for fluconazole, itraconazole, voriconazole, and amphotericin B susceptibility were read after the 24-hour incubation of each isolate on RPMI 1640 agar. Results: All Candida isolates were found susceptible to voriconazole and amphotericin B. However, all five isolates of C. glabrata were resistant to itraconazole, among which two isolates were also resistant to fluconazole. Conclusion: This study revealed that the Etest represented a simple and efficacious method for antifungal susceptibility testing of Candida species isolated from oral candidiasis patients. Therefore, voriconazole and amphotericin B should be recommended as effective alternatives for the treatment of oral candidiasis.
Abstract
Background: The necessity of performing antifungal susceptibility tests is recently increasing because of frequent cases of oral candidiasis caused by antifungal-resistant Candida species. The Etest (BioMerieux, Marcy l'Etoile, France) is a rapid and easy-to-perform in vitro antifungal susceptibility test. Objective: The purpose of this study was to determine the minimal inhibitory concentrations (MICs) of antifungal agents by using the Etest for Candida species isolated from patients with oral candidiasis. Methods: Forty-seven clinical isolates of Candida species (39 isolates of Candida albicans, 5 isolates of C. glabrata, and 3 isolates of C. tropicalis) were tested along with a reference strain (C. albicans ATCC 90028). The MIC end points of the Etest for fluconazole, itraconazole, voriconazole, and amphotericin B susceptibility were read after the 24-hour incubation of each isolate on RPMI 1640 agar. Results: All Candida isolates were found susceptible to voriconazole and amphotericin B. However, all five isolates of C. glabrata were resistant to itraconazole, among which two isolates were also resistant to fluconazole. Conclusion: This study revealed that the Etest represented a simple and efficacious method for antifungal susceptibility testing of Candida species isolated from oral candidiasis patients. Therefore, voriconazole and amphotericin B should be recommended as effective alternatives for the treatment of oral candidiasis.
참고문헌 (30)
- Kundu RV, "Fitzpatrick's dermatology in general medicine", pp.2298~2307 (2012), McGraw-Hill
- Ahn HH, "Textbook of dermatology", pp.430~437 (2014), Daehan Medical Books
- Marcos-Arias C, "In vitro activities of new triazole antifungal agents, posaconazole and voriconazole, against oral Candida isolates from patients suffering from denture stomatitis", Mycopathologia, 173, pp.35~46 (2012)
- Carvalhinho S, "Susceptibilities of Candida albicans mouth isolates to antifungal agents, essentials oils and mouth rinses", Mycopathologia, 174, pp.69~76 (2012)
- Nweze EI, "Oral Candida isolates among HIV-infected subjects in Nigeria", J Microbiol Immunol Infect, 44, pp.172~177 (2011)
- Koga-Ito CY, "Comparison between E-test and CLSI broth microdilution method for antifungal susceptibility testing of Candida albicans oral isolates", Rev Inst Med Trop Sao Paulo, 50, pp.7~10 (2008)
- Enwuru CA, "Fluconazole resistant opportunistic oro-pharyngeal Candida and non-Candida yeast-like isolates from HIV infected patients attending ARV clinics in Lagos, Nigeria", Afr Health Sci, 8, pp.142~148 (2008)
- Mareş M, "Antifungal susceptibility of 95yeast strains isolated from oral mycoses in HIV-negative and HIV-positive patients", Bacteriol Virusol Parazitol Epidemiol, 53, pp.41~42 (2008)
- Costa CR, "Species distribution and antifungal susceptibility profile of oral candida isolates from HIV-infected patients in the antiretroviral therapy era", Mycopathologia, 162, pp.45~50 (2006)
- Bagg J, "Voriconazole susceptibility of yeasts isolated from the mouths of patients with advanced cancer", J Med Microbiol, 54, pp.959~964 (2005)
- Belazi M, "Oral Candida isolates in patients undergoing radiotherapy for head and neck cancer:prevalence, azole susceptibility profiles and response to antifungal treatment", Oral Microbiol Immunol, 19, pp.347~351 (2004)
- Tapia C, "Antifungal susceptibility for Candida albicans isolated from AIDS patients with oropharyngeal and esophageal candidiasis: experience with Etest", Rev Med Chil, 131, pp.515~519 (2003)
- Davies A, "Resistance amongst yeasts isolated from the oral cavities of patients with advanced cancer", Palliat Med, 16, pp.527~531 (2002)
- Silva Mdo R, "Evaluation of Etest and macrodilution broth method for antifungal susceptibility testing of Candida sp strains isolated from oral cavities of AIDS patients", Rev Inst Med Trop Sao Paulo, 44, pp.121~125 (2002)
- rkpatrick WR, "Detection of Candida dubliniensis in oropharyngeal samples from human immunodeficiency virus-infected patients in North America by primary CHROMagar candida screening and susceptibility testing of isolates", J Clin Microbiol, 36, pp.3007~3012 (1998)
- Lass-Flörl C, "In vitro susceptibility testing in fungi: a global perspective on a variety of methods", Mycoses, 53, pp.1~11 (2010)
- Arikan S, "Current status of antifungal susceptibility testing methods", Med Mycol, 45, pp.569~587 (2007)
- Shin JH, "Antifungal drug susceptibility", Hanyang Med Rev, 26, pp.79~85 (2006)
- Sanitá PV, "Susceptibility profile of a Brazilian yeast stock collection of Candida species isolated from subjects with Candida-associated denture stomatitis with or without diabetes", Oral Surg Oral Med Oral Pathol Oral Radiol, 116, pp.562~569 (2013)
- Negri M, "Correlation between Etest, disk diffusion, and microdilution methods for antifungal susceptibility testing of Candida species from infection and colonization", J Clin Lab Anal, 23, pp.324~330 (2009)
- Samaranayake LP, "Oral mucosal fungal infections", Periodontol 2000, 49, pp.39~59 (2009)
- 이시헌, "당뇨환자에서 구강내 칸디다균의 분포에 대한 조사", 대한의진균학회지, 7(3), pp.139~148 (2002), 대한의진균학회
- Silva S, "Candida glabrata and Candida albicans co-infection of an in vitro oral epithelium", J Oral Pathol Med, 40, pp.421~427 (2011)
- Coco BJ, "Mixed Candida albicans and Candida glabrata populations associated with the pathogenesis of denture stomatitis", Oral Microbiol Immunol, 23, pp.377~383 (2008)
- Kim YJ, "Azole antifungal susceptibility testing of candida species using E test", Korean J Dermatol, 39, pp.654~659 (2001)
- Ranque S, "Interlaboratory reproducibility of Etest amphotericin B and caspofungin yeast susceptibility testing and comparison with the CLSI method", J Clin Microbiol, 50, pp.2305~2309 (2012)
- Buchta V, "Comparison of disk diffusion test and Etest for voriconazole and fluconazole susceptibility testing", Folia Microbiol (Praha), 53, pp.153~160 (2008)
- Morace G, "Antifungal susceptibility of invasive yeast isolates in Italy: the GISIA3 study in critically ill patients", BMC Infect Dis, 11, pp.130~ (2011)
- Pfaller MA, "Clinical breakpoints for voriconazole and Candida spp. revisited: review of microbiologic, molecular, pharmacodynamic, and clinical data as they pertain to the development of species-specific interpretive criteria", Diagn Microbiol Infect Dis, 70, pp.330~343 (2011)
- Scott LJ, "Voriconazole: a review of its use in the management of invasive fungal infections", Drugs, 67, pp.269~298 (2007)